We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Drug-Device Combination Could Help Treat Stroke

By HospiMedica International staff writers
Posted on 18 Nov 2015
A novel therapeutic approach combines a temporary endovascular bypass (TEB) with clot-busting nanoparticles to restore blood flow to obstructed vessels.

Developed by researchers at the Wyss Institute for Biologically Inspired Engineering (Boston, MA, USA), the New England Center for Stroke Research (NECSTR; Worcester, MA, USA) and other institutions, the drug-device combination is designed to quickly re-vascularize a vessel obstructed by a blood clot. More...
The process involves an intra-arterial stent used to open a TEB, restoring enough blood flow to trigger a shear-activated nanotherapeutic (SA-NT) agent to dissolve the blood clot.

The SA-NT agent is composed of an aggregate of biodegradable nanoparticles coated with recombinant tissue plasminogen activator (r-tPA). As blood flow increases at the TEB location, the shear force grows, and the SA-NT agent reacts to it by releasing the r-tPA-coated nanoparticles in the partially occluded blood vessels. Hemodynamic stress causes the r-tPA to concentrate at the occlusion site, binding to the clot and dissolving it, thus providing high recanalization rates while reducing vascular injury.

After the blood clot is fully dissolved, the stent is re-sheathed and harmlessly removed from the vessel. If during the process any clot fragments break off and travel away through the circulatory system, the SA-NT drug-coated nanoparticles will remain bound to them and continue to dissolve them locally wherever they go. In clinically relevant large animal studies, the TEB/SA-NT combination worked very efficiently, dissolving clots that fully occluded brain blood vessels of the same size found in humans. The study was published on October 22, 2015, in Stroke.

“What's progressive about this approach is that the temporary opening of a tiny hole in the clot, using a stent device that is already commonly used clinically, results in a local rise in mechanical forces that activate the nanotherapeutic to deploy the clot-busting drug precisely where it can best do its job,” said senior author Donald Ingber, MD, PhD, of the Wyss Institute for Biologically Inspired Engineering.

“This has been a great collaboration between experts in the field of treating stroke and experts in mechanobiology and bioengineering,” said co-first author Netanel Korin, PhD, former Wyss Technology development fellow and current assistant professor in biomedical engineering at the Israel Institute of Technology (Technion; Haifa, Israel). “We hope that one day it will have a positive impact on patients suffering from a range of medical crises resulting from blood clot occlusions.”

Related Links:

Wyss Institute for Biologically Inspired Engineering
New England Center for Stroke Research
Israel Institute of Technology



Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Endoscopy Display
E190
New
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Researchers have taken a major step toward cuff-free blood pressure monitoring (Photo courtesy of Gwyneth Moe/Boston University)

Cuff-Free Blood Pressure Monitoring Device to Improve Early Detection and Management of Hypertension

Hypertension affects nearly half of all adults in the U.S. and remains the leading cause of cardiovascular disease. Regular and accurate blood pressure monitoring is essential for managing this condition,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.